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Breast cancer is the leading cause of cancer death in women and the second most
common cancer worldwide after lung cancer.The remarkable heterogeneity of breast can-
cers influences numerous diagnostic, therapeutic, and prognostic factors. Triple-negative
breast carcinomas (TNBCs) lack expression of HER2 and the estrogen and progesterone
receptors and often contain lymphocytic infiltrates. Most ofTNBCs are invasive ductal carci-
nomas (IDCs) with poor prognosis, whereas prognostically more favorable subtypes such
as medullary breast carcinomas (MBCs) are somewhat less frequent. Infiltrating T-cells
have been associated with an improved clinical outcome in TNBCs. The prognostic role of
γδ T-cells within CD3+ tumor-infiltrating T lymphocytes remains unclear. We analyzed 26
TNBCs, 14 IDCs, and 12 MBCs, using immunohistochemistry for the quantity and patterns
of γδT-cell infiltrates within the tumor microenvironment. In both types ofTNBCs, we found
higher numbers of γδT-cells in comparison with normal breast tissues and fibroadenomas.
The numbers of infiltrating γδT-cells were higher in MBCs than in IDCs. γδT-cells in MBCs
were frequently located in direct contact with tumor cells, within the tumor and at its inva-
sive border. In contrast, most γδ T-cells in IDCs were found in clusters within the tumor
stroma. These findings could be associated with the fact that the patient’s prognosis in
MBCs is better than that in IDCs. Further studies to characterize these γδ T-cells at the
molecular and functional level are in progress.
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INTRODUCTION
Worldwide, breast cancer is the principal cause of cancer related
deaths in women in developed and in developing countries (1).
Breast cancer is a heterogeneous disease of numerous tumor sub-
types with different biological characteristics and clinical prog-
nosis (2). One subgroup with a particularly poor prognosis are
triple-negative breast carcinomas (TNBCs) characterized by lack
of estrogen receptor (ER), progesterone receptor (PR), and human
epidermal growth factor receptor 2 (HER2) expression. TNBCs
account for 10–17% of all breast carcinomas, depending on the
sensitivity of tests used to define the ER, PR, and HER2 status (3)
and frequently, these tumors contain marked lymphocytic infil-
trates (4). TNBCs are generally high-grade tumors and mostly
invasive ductal carcinomas (IDCs), although other types of breast
cancers can also be triple negative such as the medullary breast
carcinoma (MBC) (5, 6). MBCs represent only 3–5% of all breast
cancers and are characterized by a well-circumscribed margin, a
poorly differentiated nuclear grade, a high-mitotic rate, promi-
nent syncytial growth in more than the 75% of the tumor area and
a diffuse lymphoid infiltrate without intraductal components or
micro-glandular features (7). And although the MBC’s aggressive
histological characteristics are very similar to those of high-grade
triple-negative IDCs, MBCs have generally a remarkably better
prognosis than IDCs (7–9).
The association between tumor-infiltrating lymphocytes
(TILs) and the clinical outcome has been well established in many
different cancers and these findings initiated an increasing interest
in valid markers of tumor behavior and treatment response (10–
13). However, the numbers and composition of TILs may vary
depending on the types of immune responses and antigens (14).
Prominent infiltration by CD8+ T-cells has been generally associ-
ated with a better prognosis and response to therapies (15–18). In
contrast, a predominance of some CD4+ T-cell subsets within TILs
has been linked to a poorer outcome while the prognostic signif-
icance of increased numbers of regulatory T-cells (Tregs) remain
controversial and may depend on the type of tumor (19, 20).
In this context, γδ T-cells have been studied in distinct cancers
as an interesting and intriguing part of the tumor microenviron-
ment with demonstration of cytotoxicity in vitro against both solid
and hematological malignancies (21–25). However, the identifica-
tion and relevance of the different γδ T-cell subsets within the
tumor microenvironment remain poorly characterized. Vγ9Vδ2
T lymphocytes are the main subset in the human adult peripheral
blood, where γδ T-cells typically constitute about 5% of CD3+
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lymphocytes. Besides Vγ9Vδ2 T-cells, lymphocytes expressing Vδ1
are typically found in human tissues (26, 27) such as intestine,
mucosa, and skin. Even though they constitute only a small pop-
ulation of lymphocytes, γδ T-cells may play a non-overlapping
role in some human infections, autoimmunity (28), and tumor
microenvironment (29, 30). The Vγ9Vδ2 T-cell subset recognizes
phosphoantigens such as isopentenyl pyrophosphate (IPP). IPP is
produced in all higher eukaryotic cells including human cancer
cells by the mevalonate pathway. In contrast, many bacteria such
as Mycobacterium tuberculosis and protozoa such as Malaria para-
sites use the non-mevalonate (1-deoxy-d-xylulose-5-phosphate;
DOXP) pathway for the phosphoantigenic biosynthesis. (31).
These antigens are presented to human Vγ9Vδ2 T-cells bound
to the intracellular B30.2 domain of butyrophilin 3A1 (32). Anti-
gens recognized by other human γδ T-cell subsets remain poorly
defined. It has been suggested that Vδ1 recognize MHC class I
related molecules MICA, MICB, and ULBPs (21, 33). Infiltration
by γδ T-cells in human breast carcinomas and a potential role of
cytotoxic Vγ9δ2 T-cells against breast cancer cells has been initially
described by Bank et al. in 1993 (34).
Here, we analyzed the presence of γδ T-cells in the human
TIL immune microenvironment of 26 TNBCs comparing triple-
negative IDC and triple-negative MBC specimens. Since the
amounts of TILs in primary TNBCs appear to be associated with
prognosis (35), we studied these tumors, focusing on the possibil-
ity that immunohistochemistry (IHC) of γδT-cell infiltration may
help our understanding of the substantial prognostic difference
between IDCs and MBCs.
MATERIALS AND METHODS
TISSUE SPECIMENS
We analyzed 30 formalin-fixed, paraffin-embedded (FFPE) speci-
mens from patients with TNBCs that were obtained between 2003
and 2011 and preserved in the archives of the Institute of Clin-
ical Pathology of the Freiburg University Medical Center. From
these, we selected 14 IDC and 12 MBC samples with an equiva-
lent lymphocytic infiltration of at least 50% of the sample area in
HE staining (Table 1). All specimens in this study were obtained
before the patients were treated with chemotherapy or radio-
therapy. In addition, we analyzed for comparison non-malignant
breast tissues (11 normal breast tissues and 7 fibroadenomas).
Controls included sections from two TCRγδ lymphomas (kindly
provided by Prof. Müller-Hermelink, Würzburg). Negative con-
trols included TCRαβ lymphomas and isotype controls. The age
of the patients ranged between 43 and 82 years (median 57 years).
Type of tumor and staging were performed according to the clas-
sification of the Union for International Cancer Control (UICC).
All tumors included in this study were grade III according to the
modified Bloom–Richardson classification (36). MBC was diag-
nosed using the Ridolfi criteria (7). The Ethics Committee of the
University of Freiburg Medical Center approved the use of the
patient materials in this study for morphologic analyses.
IMMUNOHISTOCHEMISTRY
Sections (2µm) were mounted on Superfrost plus® Adhesion glass
slides (R. Langenbrinck, Emmendingen, Germany. Code 03-0060)
after dewaxing and rehydration. Antigen retrieval was performed
Table 1 | Characteristics of patients with grade 3 triple negative
tumors.
Diagnosis Age (mean) Tumor size mean (cm) Stage (TNM)a
N0 N1 N2
IDC (n=14) 57.5 (±11.7) 2.7 (±1.93) 10b 1 3
MBC (n=12) 59.1 (±13.3) 2.2 (±1.28) 7 4 1
aAll patients were M0.
bNumbers of patients.
Table 2 | Antibodies used in immunohistochemistry.
Antibody Dilution Retrieval
buffer
Incubation
time (min)
Anti-TCRγδ mAb 1:40 Citrate pH 6 30
CD3 antiserum Undiluted Dako pH 9 30
Caspase-3 c antiserum 1:700 Dako pH 6.1 45
using the buffers as detailed in Table 2. Endogenous peroxidase
activity was blocked by the peroxidase blocking reagent (EnVi-
sion™ FLEX Systems FLEX, Dako, Carpinteria, CA, USA. Code
S2023) for the rabbit CD3 antiserum that was detected by the per-
oxidase based detection system. For the alkaline phosphatase based
detection method [anti-TCRγδ monoclonal antibody (mAb) and
caspase-3 polyclonal antiserum], non-specific protein binding was
blocked using 3% BSA in PBS. Antigen retrieval was performed in
citrate buffer at pH 6 in a pressure cooker (anti-TCRγδ mAb), in
Dako pH 6.1 buffer (anti-caspase-3 antiserum), or in Dako pH 9
EDTA buffer (anti-CD3 antiserum) in a steam cooking machine
(Table 2). The use of a microwave oven did not produce good
results. Sections were incubated with primary antibodies that were
rabbit-anti-human CD3 polyclonal antiserum (EnVision™ FLEX
Systems Dako. Code IS503, undiluted), mouse anti-human TCRγδ
mAb (clone γ3.20, Thermo Scientific, Germany. Code 10772535,
1:40) and rabbit-anti-human cleaved-caspase-3 antiserum (Cell
Signall Corp., Danvers, MA, USA, Code 9662S, 1:700). Horseradish
peroxidase-conjugated secondary antibodies (EnVision™ FLEX
Systems Dako, Code 5007) and alkaline phosphatase-conjugated
secondary antibodies (Dako REAL™ Detection System, Alkaline
Phosphatase/RED, rabbit/mouse, Code K5005) were employed for
detection of the primary antibodies, a blue chromogen was used to
detect the cleaved-caspase-3 antibody (Dako BCIP/NBT Substrate
System Code K0598) and hematoxylin was used as a counterstain.
MICROSCOPY
Immunohistochemistry was analyzed using an Axioplan® micro-
scope (Carl Zeiss, Jena, Germany), equipped with a Axiocam®
MRc (Carl Zeiss), digital camera. Twenty randomly selected high-
power fields (HPF) of each sample were photographed (10 from
the tumor parenchyma and 10 from the stroma). A HPF 400×
was defined using a 40× objective and a 10× ocular magnifica-
tion equipped with a 26-mm ocular reticule (Carl Zeiss). For the
caspase-3 analysis, 20 HPF were considered from tumor areas.
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The cells were counted manually in all sections by two different
investigators.
STATISTICAL ANALYSIS
The unpaired t -test using the GraphPad Prism Software (Graph-
Pad Inc., San Diego, CA, USA. Version 6) was used for statistical
analysis.
RESULTS
DISTRIBUTION OF TCRγδ+ T-CELLS IN NORMAL BREAST TISSUES
We used the mAb γ3.20 that is able to detect γδ T-cells in paraffin-
embedded material (37) for IHC studies of normal breast tissues
(n= 11). There were only few CD3+ cells in normal breast sections
(Figure 1A) and very few if any expressed the TCRγδ (Figure 1B).
In contrast, infiltrations by γδ T-cells in FFPE samples of TCRγδ
lymphomas (Figure 1C) stained positive by the anti-TCRγδ mAb.
γδ T-cells were also detectable in tonsils and other normal human
tissues (data not shown).
TCRγδ+ CELLS IN IDCs AND MBCs
Next, we examined triple-negative IDCs (n= 14) and MBCs
(n= 12) for the presence of γδ T-cells since these tumors are
frequently infiltrated by lymphocytes (38). Indeed, the lympho-
cytic infiltrates in IDCs and MBCs contained many γδ T-cells
(Figure 2). Although both types of TNBCs, contained conspicuous
numbers of γδ T-cells (Table 3), the TCRγδ+ cells within the TILs
were more frequently located in the stroma of the IDC sections
(Figures 2A,B), while in the MBC sections TCRγδ+ cells were
typically located in the tumor parenchyma (Figure 2C) and at the
invasive tumor cell border (Figure 2D). Nevertheless, this distinc-
tion was not absolute since individual IDC cases contained many
γδ T-cells both in the tumor stroma and parenchyma (Figure 3).
However, there were significantly more TCRγδ+ cells within the
tumor parenchyma in MBCs than in IDCs (Table 3).
TCRγδ+ CELLS IN FIBROCYSTIC BREASTS
For comparison with the malignant tumors IDC and MBC, we
analyzed TCRγδ+ cells in fibroadenomas (n= 7) that are benign
breast lumps composed of two elements, epithelium and stroma.
Some TCRγδ+ T-cells were present in the lymphocytic infiltrates
in fibrocystic breasts (Figures 4A,B), rarely at the border or within
the epithelial component, but the amount of TCRγδ+ cells was
much lower than in the TNBC.
ACTIVATED CASPASE-3+ TUMOR CELLS IN TRIPLE-NEGATIVE IDCs AND
MBCs
Cells positive for cleaved-caspase-3 (CC3) are undergoing apop-
tosis that could be induced by interaction with cytotoxic T-cells
(39). We stained our FFPE tumor sections by IHC for the presence
of activated caspase-3. Apoptotic tumor cells were detectable in
both types of TNBC. There were significantly more CC3+ cells in
the MBC-type than in the IDC type of TNBC (Figure 5; Table 3).
DISCUSSION
The functional importance of TILs in breast cancer is controver-
sial. Most studies show that tumor-infiltrating CD8+ lymphocytes
FIGURE 1 | CD3+ andTCRγδ+ T-cells in normal breast tissue.
Representative normal breast tissue stained for CD3+ (A) and TCRγδ+
(B) T-cells. Controls included a TCRγδ+ T-cell lymphoma involving the
stomach (C). CD3+ cells are detected by the brown chromogen (A) while
TCRγδ+ cells are stained red (B,C).
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FIGURE 2 |TCRγδ+ T-cells in representative triple negative invasive
ductal carcinomas (IDCs) and medullary breast carcinomas
(MBCs). Two representative cases of IDC (A,B) and MBC (C,D) were
stained by IHC for TCRγδ+ T-cells. The tumor area is marked with T,
TCRγδ+ T-cells are detected by the red chromogen. The tumor area is
marked (“T”).
in breast cancer show a positive correlation with patient survival
(15–18, 40). FOXP3+ regulatory TILs were a favorable prognostic
factor in the HER2+/ER− breast cancers, but an adverse prognos-
tic indicator in ER+ breast cancer (19, 20, 41). In this study, we
investigated by IHC the presence of γδ T-cells in human TNBCs
comparing the IDC- and MBC-type tumors. TNBCs have attracted
much attention in recent years because there are no targeted ther-
apies for this group of breast cancers and because their profile
overlaps with that of “basal-like carcinomas” (42). Histologically,
TNBCs are more often the IDC type than the MBC one and are
frequently displaying prominent lymphocyte infiltrates. To our
knowledge, this is the first IHC analysis of γδ T-cells within TILs
in TNBCs and the first study using FFPE material. Previous stud-
ies detected γδ T-cells in human breast carcinomas by IHC in
frozen sections (34, 43). We found significant numbers of γδ T-
cells as constituents of TILs in both the IDC- and the MBC-type
of TNBC. In most IDCs, the γδ T-cells were preferentially located
in the stroma and to a lesser degree in the tumor parenchyma.
In MBCs, the γδ T-cells were mainly present within the tumor
epithelium or at its invasive border (Figure 2; Table 3). The intra-
tumoral infiltration by γδ T-cells in IDCs was heterogeneous.
Most IDC specimens showed relatively few γδ T-cells in the tumor
parenchyma in comparison with MBCs. However, in some IDCs,
a manifest intratumoral γδ T-cell infiltrate was present (Figure 3).
This may be related to the fact that TNBCs themselves constitute
a heterogeneous subgroup, with some tumors conceivably having
an intraductal and a medullary component and thus in some cases,
distinguishing between the IDC- and the MBC-type may be dif-
ficult (44). What could be the reason for the differences that we
observed in the γδ T-cell infiltration patterns between most IDCs
and the MBCs? Potential explanations include different antigens
for γδ T-cells expressed by the tumor cells or different galectins
(45) or chemokines such as CCL2 (46) present in the particular
tumor microenvironment. The apoptotic tumor cells as detected
by CC3 expression (Figure 5) might reflect the intratumoral infil-
tration by cytotoxic T-cells, such as γδ T-cells that were in direct
contact with the tumor cells (Figures 2 and 3). This is compati-
ble with previous findings showing that there are more apoptotic
tumor cells in MBC than in IDC (47, 48) and could be linked to
the overall better prognosis of MBC.
We found that γδ T-cells are rare in normal breast tis-
sues (Figure 1) and scarce within the lymphocytic infiltrates in
fibroadenomas (Figure 4) suggesting that γδ T-cells are actively
infiltrating TNBCs. The inflammatory immune responses or sol-
uble factors secreted by the tumor cells might induce infiltration
by γδ T-cells in breast carcinomas. For instance, it is possible
that some TNBCs or “basal-like” breast carcinomas (49) secrete
soluble chemokines attracting γδ T-cells. Also, it is conceivable
that TNCBs may express γδ T-cell-recognizable antigens that are
absent in other breast carcinomas and normal breast tissues.
γδ T-cells in breast carcinomas could play a protective role as
observed for CD8+ T-cells. However, one study by Ma et al.
performed on frozen sections from a heterogeneous group of
breast cancers suggested that intratumoral γδ T-cells correlated
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with the HER2 expression status, breast cancer progression and
poor patient survival rates (43). These findings are compatible
with the observation that breast cancer-derived γδ regulatory T-
cells induce immunosenescence, resulting in suppression of innate
FIGURE 3 | CD3+ andTCRγδ+ T-cells in an invasive ductal carcinoma
(IDC). IHC of an IDC with a rich lymphocytic infiltration that extends into the
tumor parenchyma (T). CD3+ T-cells are detected by the brown chromogen
(A) while TCRγδ+ cells are stained red (B). The tumor area is marked (“T”).
and adaptive immunity (50). In the study by Ma et al. (43), the
patients’ tumors were heterogeneous and the γδ T-cell numbers
correlated with Tregs, therefore, it is not possible to exclude that
other variables than γδT-cells were involved in tumor progression.
FIGURE 4 |TCRγδ+ T-cells in benign proliferative breast disease. TCRγδ
IHC in two representative fibroadenomas (from seven cases analyzed).
Fibrotic tissue (“F”) and normal breast tissue (“N”) are marked. There is a
small lymphocytic infiltrate with very few TCRγδ+ cells.
Table 3 | CD3+ andTCRγδ+ T-cells in the stroma and parenchyma of IDC and MBC.
CD3+ cells TCRγδ+ cells Cleaved-caspase-3+ cells
Stroma Parenchyma Stroma Parenchyma Tumor
IDC (n=14) 27 (±9)a 16 (±7)* 6 (±4) 2 (±2)** 4 (±2)*
MBC (n=12) 24 (±2) 24 (±9) 4 (±2) 8 (±4) 7 (±3)
aThe numbers reflect the mean positive cells per HPF (determined from the means of a total of 20 HPF counted for each patient) of IDC (n=14) and MBC patients
(n=12). SD reflects the standard variation within the cohorts of IDC and MBC patients.
*The difference between the CD3+ cells within stroma and parenchyma was statistically significant in IDC (p<0.05) but not in MBC (p=0.901). In addition, apoptotic
(CC3+) cells were significantly higher in MBC than in IDC (p<0.05).
**The difference in the higher amount of TCRγδT-cells in the tumor parenchyma in MBC than in IDC was statistically highly significant (p<0.001).
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FIGURE 5 | Apoptotic tumor cells in triple negative IDC and MBC.
Cleaved-caspase-3+ tumor cells are detected in a representative case of
IDC and MBC by a dark blue chromogen within the tumor area.
It might be interesting to investigate the TNBC infiltratingγδT-
cells at the molecular level to define their variable gene expression
and whether they can recognize breast cancer cell lines. A previous
study in colon cancer suggested that intratumoral Vδ1+ T-cells
were cytotoxic and secreted interferon-γ toward epithelial tumor
cells. Our preliminary results where we isolated γδ T-cells from
TNBCs by microdissection followed by single-cell PCR suggest
that the γδ T-cells in these tumors do not represent the Vγ9Vδ2
population in the blood, but that they express the Vδ1, Vδ3, and
Vδ4 genes (data not shown).
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